Entrar/Registro  
INICIO ENGLISH
 
Dermatología Revista Mexicana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Dermatología Revista Mexicana >Año 2017, No. 5


Moreno-Vázquez K, Ubbelohde-Henningsen T, Magallón-Zazueta L, Bonifaz A
Sertaconazol en micosis superficiales
Dermatología Rev Mex 2017; 61 (5)

Idioma: Español
Referencias bibliográficas: 51
Paginas: 386-397
Archivo PDF: 548.52 Kb.


Texto completo




RESUMEN

EL sertaconazol es un agente antifúngico imidazol benzotifeno de tercera generación, de los más recientes en el mercado, de amplio espectro contra dermatofitos, levaduras tipo Candida sp, hongos filamentosos y bacterias, principalmente cocos grampositivos; es un medicamento efectivo en el tratamiento de infecciones polimicrobianas. Tiene acción fungistática y fungicida con amplia perdurabilidad en la piel. A su vez, tiene propiedades antiinflamatorias y antipruriginosas. Su farmacodinamia se ha descrito con buena tolerabilidad, pocos efectos colaterales y altamente efectivo en las principales micosis superficiales.


Palabras clave: sertaconazol, imidazol, dermatofitos, micosis superficiales, candidosis, dermatitis seborreica, candidosis vulvovaginal.


REFERENCIAS

  1. Padilla-Desgarennes C. Micosis superficiales. Rev Fac Med 2003;46:134-137.

  2. Arenas R, Bonifaz A, López Martínez R, Estrada R, et al Tercera revisión de micosis superficiales del Consenso Nacional de Prevención, Diagnóstico y Tratamiento. Mé- xico: Facultad de Medicina, UNAM, CILAD, AMMM; 2006.

  3. Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther 2005;332-42.

  4. Carrillo-Muñoz AJ, Tur-Tur G, Giusiano G, Marcos-Arias C, et.al. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Expert Rev Anti Infect Ther: 2013;11:347-54.

  5. Farré M, Ugena B, Badenas JM, Márquez M, Roset P, Ortiz JA. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung 1992:42:752-4.

  6. Susilo R, Korting HC, Strauss UP, et al. Rate and extent of percutaneous absorption of sertaconazole nitrate after topical administration. Arzneimittelforschung 2005;55:338- 42.

  7. Marichal P, Koymans L, Willemsens S, Bellens D, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylasa (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999;145:2701-13.

  8. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003 Jun;11:272-9.

  9. Agut J, Palacín C, Sacristán A, Ortiz JA. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung 1992:5:718-20.

  10. Agut J, Palacín C, Salgado J, Casas E, et al. Direct membrane damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneim Forsch 1992;42:721-24.

  11. Croxtall JD, Plosker GL. Sertaconazole. A review of its use in the management of superficial mycoses in Dermatology and Gynaecology. Drugs 2009;69:339-59.

  12. Sur R, Babad JM, Garay M, Liebel FT, Southall MD. Antiinflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J lnvest Dermatol 2008;128:336-44.

  13. Kaur S, Sur R, Liebel FT, Southall MD. Induction of prostaglandin D2 through the p38 MAPK pathway is responsible for the antipruritic activity of setraconazole nitrate. J Invest Dermatol 2010:130:2448-56.

  14. Nigam PK. Antifungal drugs and resistance: Current concepts. Our Dermatol Online 2015:6:212-15.

  15. Borelli C, Klövekorn G, Ernst TM, Bödeker RH, et al. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol. 2007;8:371-8.

  16. Manian M, Madrasi K, Chaturvedula A, Banga AK. Investigation of the dermal absorption and irritation potential of sertaconazole nitrate anhydrous gel. Pharmaceutics 2016;7:1-14.

  17. Martín-Aragón S, Benedí J. Animicóticos dermatológicos. Farmacia Profesional 2004;18:38-49.

  18. Vennewald I, Wollin U. Cutaneous infections due to opportunistic molds: uncommon presentations. Clin Dermatol 2005;23:565-71.

  19. Palacín C, Tarragó C, Ortiz JA. Sertaconazole: pharmacology of a gynecological antifungal agent. Int J Gynaecol Obstet 2000;71:S37-46.

  20. Palacín C, Sacristán A, Ortiz JA. In vitro activity of sertaconazole. Arzneim Forch 1992;42:699.75.

  21. Carrillo-Muñoz A, Brio S, Cárdenas D, Bornay F. Sertaconazol. Actividad antifúngica frente a levaduras de interés clínico. Dermatología Peruana 2001;11:1-7.

  22. Carrillo-Muñoz AJ, Fernandez-Torres B, Guarro J. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J Chemother 2003;15:555-7.

  23. Carrillo-Muñoz AJ, Tur C, Torres J. In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J Antimicrob Chemother 1996;37:815-9.

  24. Arenas R. Dermatofitosis en México. Rev Iberoam Micol 2002;19:63-67.

  25. Savin R, Jorizzo J. The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis. Cutis 2006;78:268-4.

  26. Borrelli C, Korting HC, Bödeker RH, Neumeister C. Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis. Cutis 2010;85:107-11.

  27. Bonifaz A, Araiza J, Ramírez-Dovala S, Ponce-Olivera RM. Estudio de eficacia y seguridad de sertaconazol crema 2% en tratamiento de tiña de los pies. Dermatología CMQ 2011;9:10-15.

  28. Weinberg JM, Koestenblatt EK. Treatment of interdigital tinea pedis: once-daily therapy with sertaconazole nitrate. J Drugs Dermatol 2011;10:1135-40.

  29. Giri VP, Gupta SK, Giri OP, Matreja PS. Sertaconazole nitrate 2% cream for the treatment of tinea pedis. Nat J Lab Med 2016;5:1-5.

  30. Shivamurthy RP, Reddy SG, Kallappa R, Somashekar SA, et al. Comparison of topical anti-fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study. J Clin Diagn Res 2014;8:9-12.

  31. Sharma A, Saple DG, Surjushe A, Rao GR, et al. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses 2011:54:217-22.

  32. Ghaninejad H, Gholami K, Hashemi P, Majibabai M, et al Sertaconazole 2% cream vs miconazole 2% cream for cutaneous mycoses: a double –blind clinical trial. Clin Exp Dermatol 2009;34:837-39.

  33. Chatterjee D, Ghosh SK, Sen S, Sarkar S, et al. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. Indian J Pharmacol 2016;48:659-64.

  34. Van Esso D, Fajo G, Losada I, Vilalonga M, et.al. Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clinical Ther 1995;17:264-9.

  35. López-Olmos J, Lerma E, Parra I. Comparación de fenticonazol frente a sertaconazol en dosis única para el tratamiento de las candidiasis vulvovaginales: estudio prospectivo y multicéntrico de un año. Clin Invest Gin Obst 2003;30:10-7.

  36. Dellenbach P, Thomas JL, Guerin V, Ochsenbein E, et al. Topical treatment of vaginal candidosis with sertoconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet 2000;71:S47-52.

  37. Wang PH, Chao HT, Chen CL, Yuan CC. Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. J Chin Med Assoc 2006;69:259.63.

  38. Lutsevich KA, Reschetko OV, Rogozhina IE, Lutsevich NF. Clinical effectiveness of sertaconazole (Zalain) in the logal treatment of vulvovaginal candidiasis during pregnancy. Russian Bull Obstetrician-Gynaecologist 2008;3:77-80.

  39. Quereux C, Gelas B, Chevallier T, Petit F, Micheletti MC. Evaluation of the efficacy and speed of action of sertaconazole nitrate suppository and cram combined treatment for vulvovaginal candidiasis. Gynecol 2000;28:238-44.

  40. Alomar C, Bassas S, Casas M, Crespo V, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 1992:42:767-73.

  41. Bonifaz A, Tirado-Sánchez A, Graniel MJ, Mena C, et al. The efficacy and safety of sertaconazole cream (2%) in diaper dermatitis candidiasis. Mycopathologia 2013;175:249-54.

  42. Elewski BE, Cantrell WC. An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis. J Drugs Dermatol 2011:10:895-9.

  43. Balighi K, Ghodsi SZ, Daneshpazhooh M, Ghale-Baghi S, et al. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial. Int J Womens Dermatol 2016;23:107-110.

  44. Lotti T, Goldust M, Rezaee E. Treatment of seborrheic dermatitis, comparison of sertaconazole 2% cream versus ketoconazole 2% cream. J Dermatol Treat 2013:1-3.

  45. Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol 2013;59:25-9.

  46. Goldust M, Rezaee, Raghifar R, Hemayat S. Treatment of seborrheic dermatitis: The efficiency of sertaconazole2% cream vs. tacrolimus 0.03% cream. Ann Parasitol 2013;59:73-7.

  47. Nasarre J, Umbert P, Herrero E, Rosef P, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of pityriasis versicolor. ArzneimmitelForschung 1992;42:764-67.

  48. Padilla-Desgarennes C. Pitiriasis versicolor 2005; Dermatología Rev Mex 2005;49:157-67.

  49. Fierro-Arias L, Echevarría-Keel J, Huesca A, Bonifaz A. Tiña negra palmar tratada con sertaconazol crema (2%). Dermatol Rev Mex 2016;60:361-63.

  50. Stander S, Metz M, Ramos MH, Maurer M, et al. Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehiclecontrolled, multi-centre clinical trial of efficacy, safety and local tolerability. Acta Derm Venereol 2016;96:792-96.

  51. Radwan SAA, El Meshad AN, Shoukri RA. Microemulsion loaded hydrogel as a promising vehicle for dermal delivery of the antifungal sertaconazole: design, optimization and ex vivo evaluation. Drug Dev Ind Pharm 2017;43:1351- 1365.



>Revistas >Dermatología Revista Mexicana >Año2017, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019